Edgewise Therapeutics, Inc. (EWTX)
30.91
+0.82
(+2.73%)
USD |
NASDAQ |
Feb 24, 16:00
31.00
+0.09
(+0.29%)
After-Hours: 20:00
Edgewise Therapeutics Research and Development Expense (Quarterly) : 36.96M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Glaukos Corp. | 43.65M |
| Nuvalent, Inc. | 83.84M |
| Neurocrine Biosciences, Inc. | 258.20M |
| Dynavax Technologies Corp. (DELISTED) | 19.12M |
| Omeros Corp. | 15.76M |